In this work, we tested the selective PDE4 inhibitor roflumilast mainly because this drug has been tested in phase II and III clinical trials (Rabe, 2011) and has been approved as an adjuvant to reduce the risk of exacerbation in patients with severe COPD (Schudt et al., 2011). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.